Mersana Therapeutics Inc (NASDAQ:MRSN) has a beta value of 1.63 and has seen 3.19 million shares traded in the last trading session. The company, currently valued at $71.89M, closed the last trade at $0.58 per share which meant it lost -$0.03 on the day or -4.48% during that session. The MRSN stock price is -982.76% off its 52-week high price of $6.28 and 15.52% above the 52-week low of $0.49. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.99 million shares traded. The 3-month trading volume is 4.63 million shares.
The consensus among analysts is that Mersana Therapeutics Inc (MRSN) is Buy stock at the moment, with a recommendation rating of 1.36. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 5 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.16.
Mersana Therapeutics Inc (NASDAQ:MRSN) trade information
Sporting -4.48% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the MRSN stock price touched $0.58 or saw a rise of 23.91%. Year-to-date, Mersana Therapeutics Inc shares have moved -59.30%, while the 5-day performance has seen it change -22.40%. Over the past 30 days, the shares of Mersana Therapeutics Inc (NASDAQ:MRSN) have changed -9.13%. Short interest in the company has seen 9.47 million shares shorted with days to cover at 1.02.
Wall Street analysts have a consensus price target for the stock at $3, which means that the shares’ value could jump 80.67% from current levels. The projected low price target is $3.0 while the price target rests at a high of $3.0. In that case, then, we find that the current price level is -417.24% off the targeted high while a plunge would see the stock gain -417.24% from current levels.
Mersana Therapeutics Inc (MRSN) estimates and forecasts
The company’s shares have lost -52.68% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -15.77%.
10 analysts offering their estimates for the company have set an average revenue estimate of 7.64M for the current quarter. 6 have an estimated revenue figure of 5.2M for the next ending quarter. Year-ago sales stood 10.7M and 9.24M respectively for this quarter and the next, and analysts expect sales will shrink by -28.60% for the current quarter and -15.77% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 11.93% over the past 5 years. Earnings growth for 2025 is a modest 58.87% while over the next 5 years, the company’s earnings are expected to increase by 20.92%.
MRSN Dividends
Mersana Therapeutics Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Mersana Therapeutics Inc (NASDAQ:MRSN)’s Major holders
Insiders own 1.50% of the company shares, while shares held by institutions stand at 92.17% with a share float percentage of 93.58%. Investors are also buoyed by the number of investors in a company, with Mersana Therapeutics Inc having a total of 166.0 institutions that hold shares in the company. The top two institutional holders are ECOR1 CAPITAL, LLC with over 19.36 million shares worth more than $38.92 million. As of 2024-06-30, ECOR1 CAPITAL, LLC held 15.9479% of shares outstanding.
The other major institutional holder is VR ADVISER, LLC, with the holding of over 11.33 million shares as of 2024-06-30. The firm’s total holdings are worth over $22.77 million and represent 9.2519% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . As of Sep 30, 2024 , the former fund manager holds about 2.81% shares in the company for having 3.47 shares of worth $2.02 million while later fund manager owns 3.22 shares of worth $1.87 million as of Nov 30, 2024 , which makes it owner of about 2.60% of company’s outstanding stock.
